[New Drugs for the Treatment of Multidrug-resistant Tuberculosis (MDR-TB)]

T Schaberg; R Otto-Knapp; T Bauer

doi:10.1055/s-0034-1391920

[New Drugs for the Treatment of Multidrug-resistant Tuberculosis (MDR-TB)]

Pneumologie. 2015 May;69(5):282-6. doi: 10.1055/s-0034-1391920. Epub 2015 May 13.

[Article in German]

Authors

T Schaberg¹, R Otto-Knapp², T Bauer²

Affiliations

¹ Zentrum für Pneumologie, Agaplesion Diakonieklinikum Rotenburg.
² Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (DZK e.V.) und Klinik für Pneumologie der Lungenklinik Heckeshorn im Helios Klinikum Emil von Behring, Berlin.

PMID: 25970122
DOI: 10.1055/s-0034-1391920

Abstract

This article summarizes the state of development of new drugs for the treatment of multidrug-resistant tuberculosis. We focused on delamanid, bedaquiline, pretomanid, SQ 109 and sutezolid.

Publication types

Review

MeSH terms

Antitubercular Agents / administration & dosage
Antitubercular Agents / adverse effects
Evidence-Based Medicine
Humans
Treatment Outcome
Tuberculosis, Multidrug-Resistant / drug therapy*
Tuberculosis, Multidrug-Resistant / microbiology*

Substances

Antitubercular Agents